Immunoglobulin M Paraproteinaemias

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Monoclonal paraproteinaemia is a frequent hematology referral, ranging from incidental findings to serious malignancies.
• Immunoglobulin M (IgM) paraproteinaemias, while comprising 15-20% of monoclonal proteins, present unique clinical challenges.
• IgM paraproteins are linked to lymphoplasmacytic lymphoma, other B-cell neoplasms, and specific monoclonal gammopathies of clinical significance.

Purpose of the Study:

• To provide a clinical overview of IgM paraproteinaemias.
• To discuss diagnostic and therapeutic challenges associated with IgM paraproteinaemias.
• To highlight key advances impacting future patient management.

Main Methods:

• Review of clinical and histopathologic findings in IgM paraproteinaemias.
• Discussion of molecular biology insights, including MYD88 L265P mutations.
• Analysis of clinical manifestations related to the large molecular weight of IgM multimers.

Main Results:

• IgM paraproteins are more frequently associated with lymphoplasmacytic lymphoma than multiple myeloma.
• The large molecular weight of IgM multimers contributes to a distinct spectrum of clinical manifestations.
• Differential diagnosis of IgM-associated B-cell and plasma cell dyscrasias can be complex.

Conclusions:

• IgM paraproteinaemias pose significant diagnostic and therapeutic challenges.
• Clinical and histopathologic findings remain vital despite advances in molecular biology.
• Future management strategies will be influenced by ongoing research and understanding of these disorders.